Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.
about
Folate receptor-β constitutes a marker for human proinflammatory monocytesCCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritisT Cell Migration in Rheumatoid ArthritisCellular targeting in autoimmunityHydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expressionAgarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple ChemokinesIdentification of Motile Sperm Domain-Containing Protein 2 as Regulator of Human Monocyte Migration.Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury ResponsePET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis.The CCR5Δ32 polymorphism in Brazilian patients with sickle cell diseaseChemokine-mediated inflammation in the degenerating retina is coordinated by Müller cells, activated microglia, and retinal pigment epitheliumG protein-coupled receptors--recent advancesTranscriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway.CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort studyInflammatory monocyte effector mechanisms.Maternal micronutrient supplementation suppresses T cell chemokine receptor expression and function in F1 miceNf1+/- monocytes/macrophages induce neointima formation via CCR2 activation.The Induction of Circulating, ACAID-Inducing Monocytes Requires CCR2/CCL2-Dependent Migration of Circulating F4/80(+) Cells into the Anterior ChamberCirculating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2.Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic ApproachesTargeting inflammation in cardiovascular diseases. still a neglected field?A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.Mechanisms regulating chemokine receptor activity.Therapeutic potential of chemokine receptor antagonists for liver disease.Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.Role of inflammation in HIV-1 disease progression and prognosis.Macrophages in solid organ transplantation.The Mononuclear Phagocyte System in Organ Transplantation.Successes and failures of chemokine-pathway targeting in rheumatoid arthritis.Monocyte-mediated defense against bacteria, fungi, and parasites.Properties of 7ND-CCL2 are modulated upon fusion to Fc.Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy.A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites.CSF-1 regulates the function of monocytes in Crohn's disease patients in remission.Empty liposomes induce antitumoral effects associated with macrophage responses distinct from those of the TLR1/2 agonist Pam3CSK 4 (BLP).Nano-scale treatment for a macro-scale disease: nanoparticle-delivered siRNA silences CCR2 and treats myocarditis.Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists.
P2860
Q24300693-226A99DF-739A-4B41-9B30-B9FBD362380AQ24701793-1E17AD1D-38B9-4F1D-A3F1-E197E307DE78Q26797338-84CF42E9-EABA-452B-A9DA-08C785368BDEQ26824580-6AFD1552-9A56-44E8-955C-F7BD16664EABQ27332432-E96C30F7-E47F-4F60-B5C2-A59E258D859DQ30850587-F239C080-6FFE-4971-ABBF-15D6B2E70C39Q33112705-1FE091E1-9943-4BE8-A306-9E8EA4D812F4Q33722663-46121DED-D034-40B2-BBD3-230912B5AFADQ34609062-7A5F5BA7-374B-4FA9-A0F8-50E0381ED18BQ34762728-45ABA468-F678-4A59-9D41-3A2B52FFB8D1Q35021422-BCCF4B35-D9B8-4C06-B8F7-19BBD0C227ACQ35065927-93DE0023-DD98-4F74-A8A4-EF27BFEAA2AAQ35148038-1B1F9A78-6D0E-4CD9-8E0A-6F3B634098BCQ35617726-0709DD37-EEA5-4202-B654-418A710E4E25Q35688241-099AC3EB-9531-409E-896B-FD0B1797A7F6Q36030208-0640D47E-002B-4E7D-BB17-B65B26F7968EQ36608863-6CFACDAD-1271-4D3B-B2F0-7D4369CB4D9DQ36867193-F7F07506-4926-4300-B4A5-5CAAB64861EEQ37087273-659E486F-9897-4CB8-B9E0-EA73E79BAFAFQ37252004-1973DBBE-3B98-4C4D-8316-4B9FE0AD452FQ37925018-BA9D0983-F7AC-4301-BEDE-7298385279F7Q37936463-C0935B3F-0308-429A-A313-A72B5DC5B80DQ37942973-695E08D2-35AA-42BF-93D9-59C39ACE08C3Q37960533-1899BC22-5AB3-4D82-98A9-A7AD7D37072DQ38083321-84A8EC15-E354-4F14-9528-4F6E291DDC1DQ38183454-1E096F4E-D277-4C7E-A08B-CA6FB32F3C4FQ38194688-DE023B96-7236-4E81-BD62-A84BE7206430Q38646389-4BD22746-010E-403E-BE98-60F06D7A423AQ38647749-0F496A94-1D11-4AE6-B202-FC19F8207AACQ38791792-6A312172-930B-4ECB-AD4C-8C992CF860BEQ39385980-529205A7-FA7E-4D0C-8382-2517310B4419Q39550213-F529AD8D-496F-46BA-BDCD-1A8606C4CA77Q40675523-E7BB9F92-41BC-407D-B9ED-95055D15EC15Q41348794-6CAA04F1-CC15-4857-848D-380007074672Q41945153-78089D8C-F559-4A6B-997D-9FC1A8829461Q42198256-CE5A5A1B-4F44-4DDB-A07A-65E35CE6B761Q42442630-98C054AF-3538-494A-8F6B-45F570B3112FQ42479673-51159835-33CF-407E-98A5-8E5C842D199DQ45950376-8013292C-5C32-4184-97F0-DA9E20CC1765Q51019605-8485EE75-2E21-4F01-A219-495F8F481E2A
P2860
Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@en
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@nl
type
label
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@en
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@nl
prefLabel
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@en
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@nl
P2860
P356
P1476
Dual targeting of CCR2 and CCR ...... c and cardiovascular diseases.
@en
P2093
Qihong Zhao
P2860
P356
10.1189/JLB.1009671
P577
2010-04-01T00:00:00Z